Werewolf Therapeutics Inc (HOWL)
$2.75
+0.7
(+34.15%)▲
Live
Performance
- $2.56$3.12$2.75
6.93%
Downside
Day's Volatility :17.96%
Upside
11.86%
- $1.57$8.19$2.75
42.78%
Downside
52 Weeks Volatility :80.8%
Upside
66.44%
Returns
| Period | Werewolf Therapeutics Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -25.18% | 3.6% | 0.0% |
6 Months | -66.34% | 10.2% | 0.0% |
1 Year | 15.17% | 19.6% | 0.0% |
3 Years | -87.19% | 16.8% | -23.0% |
Highlights
Market Capitalization | 89.6M |
Book Value | $2.38 |
Earnings Per Share (EPS) | -1.38 |
Wall Street Target Price | 12.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1658.79% |
Return On Assets TTM | -21.51% |
Return On Equity TTM | -48.27% |
Revenue TTM | 9.3M |
Revenue Per Share TTM | 0.24 |
Quarterly Revenue Growth YOY | -85.9% |
Gross Profit TTM | -37.4M |
EBITDA | -56.5M |
Diluted Eps TTM | -1.38 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.65 |
EPS Estimate Next Year | -1.94 |
EPS Estimate Current Quarter | -0.38 |
EPS Estimate Next Quarter | -0.37 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 336.36%
Technicals Summary
Sell
Neutral
Buy
Werewolf Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Werewolf Therapeutics Inc | -2.38% | -66.34% | 15.17% | -87.19% | -87.27% |
 Regeneron Pharmaceuticals, Inc. | -9.28% | 10.06% | 24.53% | 74.0% | 232.45% |
 Novo Nordisk A/s | -4.54% | -5.72% | 21.59% | 126.2% | 349.01% |
 Alnylam Pharmaceuticals, Inc. | 8.87% | 102.98% | 82.67% | 44.83% | 241.09% |
 Vertex Pharmaceuticals Incorporated | 5.0% | 20.77% | 31.37% | 158.16% | 163.17% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Werewolf Therapeutics Inc | 0.66 | NA | NA | -1.65 | -0.48 | -0.22 | NA | 2.38 |
Regeneron Pharmaceuticals, Inc. | 26.41 | 26.41 | 1.37 | 44.9 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 40.21 | 40.21 | 1.81 | 3.36 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.42 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.59 | 0.18 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Werewolf Therapeutics Inc | Buy | $89.6M | -87.27% | 0.66 | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $110.0B | 232.45% | 26.41 | 32.04% |
Novo Nordisk A/s | Buy | $529.8B | 349.01% | 40.21 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $38.1B | 241.09% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $128.7B | 163.17% | 32.84 | -4.74% |
Insights on Werewolf Therapeutics Inc
Increasing Revenue
Revenue is up for the last 2 quarters, 742.0K → 1.14M (in $), with an average increase of 35.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 5 quarters, -5.09M → -17.24M (in $), with an average decrease of 37.2% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 82.4%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 132.0%
Institutional Holdings
RA Capital Management, LLC
14.06%Mpm Asset Management, LLC
9.80%Partner Fund Management LP
7.42%MPM Oncology Impact Management LP
5.46%Bank of America Corp
4.91%Adage Capital Partners Gp LLC
4.58%
Company Information
we are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.
Organization | Werewolf Therapeutics Inc |
Employees | 45 |
CEO | Dr. Daniel J. Hicklin Ph.D. |
Industry | Services |
